Xiaoban Xin’s practice focuses on patent prosecution and portfolio development, strategy, and due diligence, with a particular emphasis on life sciences companies and products. Xiaoban also has extensive experience in the fields of medical device, chemical engineering and materials, energy and clean tech, mechanical engineering, and software. Prior to his legal career, Xiaoban was awarded a doctorate in Biomedical Sciences, and his scientific background and experience is a significant asset in communicating with and guiding life science clients. Following his doctorate, he did postgraduate work and research at the Johns Hopkins University School of Medicine, where he studied the molecular mechanisms underlying diabetes and retinopathy. His research has been published in a number of prestigious professional journals.
In building patent portfolios, he begins with a deep dive into each client’s business and technology, in order to develop an in-depth understanding of the science at issue. Based on this information, he then works with the client to devise a patent asset strategy that serves their specific business purposes. This strategy is then translated into a series of patent applications based on it, as well as on the client’s individual stage in the business lifecycle.
Depending on the stages and business models, a client’s goal of patent assets development can range from building as comprehensive a patent portfolio as possible, to creating as broad a potential market as they can, to prioritizing a defined, highly defensible market space to compete in a crowded, more mature market. By tailoring strategy to both a company’s products and its individual market situation, Xiaoban helps clients leverage the strongest, most strategic approach to their intellectual property.
In addition to portfolio development and patent prosecution, Xiaoban also assists clients with due diligence projects in anticipation of a transaction. This includes analysis of the patent landscape to understand the IP position of competitors, identifying potential risks, and developing strategies for handling risks. He also engages in evaluation of the strength, scope, and potential of patents of prospective partners and competitors, and general due diligence in support of investment or mergers and acquisitions projects.
In these roles, he works with in-house counsel, senior management, and technology transfer office managers. For each of these client categories, Xiaoban works to help translate innovation into commercially viable products. He acts as the bridge between the inventor and the marketplace, helping the former enter the later with a maximum of upside and, as much as possible, a minimum of risk.
Thanks to his scientific background, Xiaoban is exceptionally skilled at both communicating with and analyzing cutting-edge inventions, particularly in the biotechnology and pharmaceutical fields. He speaks the language, science, of his clients, which makes him an invaluable asset to anyone seeking to move an innovation into the marketplace. Whatever the invention, marketplace, or situation, he’s a major asset to anyone seeking to protect their intellectual property.
Xiaoban is fluent in Mandarin Chinese.
Xin X, “Patent Eligibility of 3D-Printed Organs,” AIPLA Quarterly Journal, Vol. 44, No. 1, 2016
Tan Y, Xin X, Coffey FJ, Wiest DL, Dong LQ, Testa JR. Appl1 and Appl2 are Expendable for Mouse Development But Are Essential for HGF-Induced Akt Activation and Migration in Mouse Embryonic Fibroblasts. J Cell Physiol. (2016) 231(5): 1142-50.
Babapoor-Farrokhran S, Jee K, Puchner B, Hassan SJ, Xin X et al. Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy. Proc Natl Acad Sci USA. (2015) 112(23):E3030-9.
Ryu J, Galan AK, Xin X et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. (2014) 7(4): 1127-38.
Krispel C, Rodrigues M, Xin X, Sodhi A. Ranibizumab in diabetic macular edema. World J Diabetes. (2013) 4(6): 310-8.
Xin X, Rodrigues M, Umapathi M et al. Up-regulation of Angiopoietin-like 4 Promotes Vascular Permeability in Ischemic Retinal Disease. Proc. Nad. Acad. Sci USA. (2013) 110(36): E3425-34.
Rodrigues M, Xin X et al. VEGF Secreted by Hypoxic Miiller Cells Induces MMP-2 Expression and Activity in Endothelial Cells to Promote Retinal Neovascularization in Proliferative Diabetic Retinopathy. Diabetes. (2013) 62(II): 3863-73.
Xin X, Zhou L, Reyes CM, Liu F, Dong LQ. APPL1 mediates adiponectin-stimulated p38 MAPK activation by scaffolding TAKI-MKK3-p38 MAPK pathway. Am. J. Physiol. Endocrinol. Metab. (2011) 300(1): E103-10.
Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, Dong LQ. Yin-Yang regulation of adiponectin signalling by APPL isoforms in muscle cells. Biol. Chem. (2009) 284(46): 31608-31615.
Wang C, Liu M, Riojas RA, Xin X, Gao Z, Zeng R, Wu J, Dong LQ, Liu F. PKC(theta)-dependent phosphorylation of PDK1 at SER504 and SER532 constributes to palmitate-induced insulin resistance. J. Biol. Chem. (2009) 284(4): 2038-2044.
Liu M, Zhou L, Xu A, Lams KS, Wetzel MD, Xiang R, Zhang J, Xin X, Dong LQ, Liu F. A disulfide-bond A oxidoreductase-like protein (DsbA-L) regulates adiponectin multimerization. Proc. Nad. Acad. Sci. USA. (2008) 105(47): 18302-18307.
Chen T, Cui J, Liang Y, Xin X, Owen Young D, Chen C, Shen P. Identification of human liver mitochondrial aldehyde dehydrogenase as a potential target for microcystin-LR. Toxicology. (2006) 220(1): 71-80.
Zhao S, Shen P, Zhou Y, Wei Y, Xin X, Hua Z. Selecting peptide ligands and microcystin-LR from phage displayed random libraries. Environ. Int. (2005) 31(4): 535-541.
J.D., The George Washington University Law School (Editor, American Intellectual Property Law Association Quarterly Journal)
Ph.D., Biomedical Sciences (Cellular and Molecular Biology), University of Texas Health Science Center at San Antonio
B.S., Biological Science, Nanjing University (China)
- Mandarin Chinese
Bar & Court Admissions
- District of Columbia
- U.S. Patent and Trademark Office